|
Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus Clinical research trials and Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus. Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus clinical trial. Subjects frequently obtain the most expert healthcare possible for their Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
For Condition: recurrent gastric cancer,Adenocarcinoma of the Esophagus,stage 4 esophageal cancer,squamous cell carcinoma of the esophagus,recurrent esophageal cancer,stage 4 gastric cancer,adenocarcinoma of the stomach
Status: No longer recruiting
Sponsor(s): Southwest Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic or recurrent cancer of the esophagus.
Details: OBJECTIVES: - Determine the 6-month survival rate of patients with metastatic or recurrent carcinoma of the esophagus or gastroesophageal junction treated with gemcitabine and irinotecan. - Determine the qualitative and quantitative toxic effects of this regimen in these patients. OUTLINE: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 2 years. PROJECTED ACCRUAL: A total of 30-55 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic or recurrent carcinoma of the esophagus or gastroesophageal junction - Squamous cell carcinoma OR - Adenocarcinoma - No known brain metastases PATIENT CHARACTERISTICS: Age: - 18 to 100 Performance status: - Zubrod 0-2 Life expectancy: - Not specified Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Not specified Renal: - Creatinine no greater than 1.5 times upper limit of normal Cardiovascular: - No uncontrolled hypertension - No unstable angina - No symptomatic congestive heart failure - No myocardial infarction within the past 6 months - No serious uncontrolled cardiac arrhythmia Gastrointestinal: - No active inflammatory bowel disease - No significant bowel obstruction - No chronic diarrhea Other: - Not pregnant or nursing - Fertile patients must use effective contraception - No active infection requiring systemic therapy - No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 28 days since prior biologic therapy - No prior biologic therapy for metastatic or recurrent disease - No concurrent sargramostim (GM-CSF) - No concurrent immunotherapy for tumor Chemotherapy: - At least 28 days since prior chemotherapy - No prior chemotherapy for metastatic or recurrent disease - No prior gemcitabine or irinotecan - Prior adjuvant or neoadjuvant chemotherapy at time of initial diagnosis of localized disease allowed - No other concurrent chemotherapy for tumor Endocrine therapy: - See Disease Characteristics - At least 28 days since prior endocrine therapy - No prior endocrine therapy for metastatic or recurrent disease - No concurrent hormonal therapy for tumor Radiotherapy: - At least 28 days since prior radiotherapy - No prior radiotherapy for metastatic or recurrent disease - Prior adjuvant or neoadjuvant radiotherapy at time of initial diagnosis of localized disease allowed - No concurrent radiotherapy for tumor Surgery: - Prior thoraco-abdominal surgery allowed - At least 3 weeks since prior surgery and recovered Other: - No other concurrent anti-cancer therapy for tumor
Total Enrollment:
Location and Contact Information:
Overall Study Official:
StephenWilliamson, Study Chair, University of Kansas
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
United States
CCOP - Columbia River Program
Portland, Oregon, 97225
United States
CCOP - Southeast Cancer Control Consortium
Winston Salem, North Carolina, 27104-4241
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
Tripler Army Medical Center
Honolulu, Hawaii, 96859-5000
United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813-2424
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
MBCCOP-Howard University Cancer Center
Washington D.C., District of Columbia, 20060
United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
University of Rochester Medical Center
Rochester, New York, 14642
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
OHSU Cancer Institute
Portland, Oregon, 97239
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
United States
Veterans Affairs Medical Center - Charleston
Charleston, South Carolina, 29401-5799
United States
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195-9001
United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
United States
University of Texas Medical Branch
Galveston, Texas, 77555-0565
United States
CCOP - Northwest
Tacoma, Washington, 98405-0986
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4095
United States
CCOP - Dayton
Kettering, Ohio, 45429
United States
University of California Davis Medical Center
Sacramento, California, 95817
United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
United States
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0912
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40502-2236
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7353
United States
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
United States
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
United States
CCOP - Scott and White Hospital
Temple, Texas, 76508
United States
Swedish Cancer Institute
Seattle, Washington, 98104
United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0501
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
United States
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, 63141
United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
United States
Veterans Affairs Medical Center - Houston
Houston, Texas, 77030
United States
Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
Phoenix, Arizona, 85012
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
St. Louis University Health Sciences Center
St. Louis, Missouri, 63110
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7845
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
United States
Additional Information:
Study ID Numbers: CDR0000068515; SWOG-S0101
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012363
Other Adenocarcinoma Of The Stomach Studies:
1. Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
2. Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
3. Irinotecan in Treating Patients With Advanced Cancer of the Stomach
4. Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
5. Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
Related Studies:
Other adenocarcinoma of the stomach Clinical Trials
Other Kentucky Clinical Trials
Other Lexington Clinical Trials
Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
|
|
|
|
|
|
|
|